Key Highlights

  • Danaher shares are trading at $213.77 in Thursday's session, down 3.51%.
  • Julie Sawyer Montgomery assumed the roles of President and CEO and joined the board, with Rainer Blair staying on as senior advisor until March 31, 2027.
  • The shares had gained about 19% over the prior 90 days, prompting profit-taking in richly valued life sciences names.
  • Third-quarter Earnings on October 21 will be the first report under the new CEO.

New CEO Takes Over as Valuation Questions Mount

Danaher (NYSE:DHR) is trading lower in Thursday's session as Julie Sawyer Montgomery formally assumed the roles of President and CEO of the life sciences and diagnostics company and joined its board. The shares are down 3.51% at $213.77 and underperforming a healthcare sector that has also softened.

The Leadership change was previously announced on August 3. Commentary points instead to profit-taking in richly valued life sciences names after a roughly 19% gain over 90 days, with the stock trading near 38 times trailing earnings.

A Planned Handoff With Blair Staying On

Sawyer Montgomery joined Danaher in 2017 and has held roles spanning commercial operations, R&D and Business leadership, including work on the Danaher Business System. Rainer Blair will serve as senior advisor until March 31, 2027 to support the transition.

Bioprocessing Strength Competes With a Lowered Growth Outlook

Investors are weighing order strength in bioprocessing against a lowered full-year core growth outlook and weakness in respiratory testing. Brokerages recently lifted price targets to $250, and the broader sector is under pressure, with Thermo Fisher Scientific (NYSE:TMO) also lower as the 10-year Treasury Yield stays near multi-decade highs.

October 21 Earnings Will Be the New CEO's First Test

Third-quarter results on October 21 will be the first report under the new leadership. The stock trades within a 52-week range of $160.93 to $242.80, and the outcome will show whether bioprocessing strength can outweigh the softer parts of the outlook.